Trial Profile

Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Mar 2024 Status changed from recruiting to active, no longer recruiting.
13 Dec 2022 Results of post hoc analysis of this trial to explore the safety and effectiveness of extended dosing with damoctocog alfa pegol presented at the 64th American Society of Hematology Annual Meeting and Exposition.
09 Nov 2022 Results of post-hoc subgroup analysis (n=31; data cut-off 31 August 2021) assessing effectiveness and safety of damoctocog alfa pegol utilisation during routine clinical practice, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com